FDA Calendar for MannKind Corporation (MNKD)

| Register (free)
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, is an ultra rapid-acting insulin that has completed Phase III clinical trials evaluating its safety and efficacy in the treatment of diabetes. AFRESA consists of the Company’s Technosphere particles, onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled deep into the lung using the Company’s AFRESA inhaler.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
Afrezza Other Pending DecisionPhase 3


Events

No future events listed at this time, please check back later.
5 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

MNKD

$2.17
-0.30 -12.15%
2/3/2012 4:00:00 PM

Sponsors

Other Links